Brief: Virios Therapeutics reports Q2 results
11/08/2022 12:09
Aug 11 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS ANNOUNCES SECOND QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* Q2 LOSS PER SHARE $0.44
* TOP LINE FORTRESS STUDY DATA EXPECTED IN SEPTEMBER 2022
* AS OF JUNE 30, 2022, VIRIOS THERAPEUTICS' CASH TOTALED
$7.7
MILLION
* BELIEVES IT WILL HAVE SUFFICIENT RESOURCES TO FUND ITS
PLANNED
OPERATIONS THROUGH END OF 2022
Source text for Eikon: ID:nBw2RZKCna
Further company coverage: VIRI.O
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study